Delivery Order SPE2DB22D2007-SPE2DB23FJ4WY
Award Date 8/8/23
Potential Completion Date 8/29/23
Potential Value $7.9K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $17,009.24 delivery order to AmerisourceBergen Drug Corp for Tecentriq 840 mg/14 ml vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a major distribution hub for federal pharmaceutical...
- Defense Logistics Agency awarded a $8,730.60 firm fixed price delivery order to Amerisourcebergen Drug Corp for TECENTRIQ 840 MG/14 ML VIAL 14ML pharmaceutical products. As the parent company, Amerisourcebergen Corporation will provide the products, with performance taking place in Conshohocken, Pennsylvania by November 8, 2023. No set-aside designation was used for this award made under an existing vehicle to supply pharmaceuticals in support of DLA and Department of Defense health programs.
- The Defense Logistics Agency awarded a delivery order valued at $9,344.66 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 ml vials on January 28, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The delivery order is scheduled for completion by February 19, 2026, with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. This contract represents a task order under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,344.66 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 ml vials on January 28, 2026. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of February 19, 2026, with performance executed from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,252.30 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 mL vials on November 5, 2025. This competitively awarded, firm fixed-price delivery order is set to conclude by November 28, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $17,009.24 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 ml vials. This firm fixed-price, competitively awarded contract was issued on August 12, 2025, with an ultimate completion date of September 3, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside acquisition, this delivery order was open to competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This $4,252.30 delivery order, which carries a firm fixed price contract type with no set-aside designation, is scheduled for completion by November 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. Tecentriq is a specialized pharmaceutical product used in oncology treatment, reflecting the critical role...
- The Defense Logistics Agency awarded a $17,009.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Tecentriq (atezolizumab) 840 mg/14 mL vials on May 19, 2025, with completion targeted for June 10, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, which carries a $999,999,999 ceiling and runs through December 2026. The pharmaceutical distributor is...
- The Defense Logistics Agency awarded a $25,189 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tecentriq Hybridza 1,875 mg 15 ml pharmaceutical product. This is a non-set-aside competitive award with an ultimate completion date of September 30, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,504.62 on September 19, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 10, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside award made through open competition, reflecting AmerisourceBergen's demonstrated capability to fulfill...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB23FJ4WYDelivery Order
The Defense Logistics Agency awarded a $7,857.72 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of TECENTRIQ 840 MG/14 ML vials. Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, will deliver the product from its location in Conshohocken, Pennsylvania to the Defense Logistics Agency by August 29, 2023 to fulfill requirements under the agency's pharmaceutical supply contracts. No subcontractors or set aside designations were identified. The delivery order provides cancer treatment medications to support the Department of Defense's healthcare programs.
Generated 12/15/23, 2:05 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 8/8/23 |